DISORDER DRUG PSYCHOTHERAPEUTIC

MDD Sertraline 50 mg OD ​1 month CBT

(5/9) A SAD FACES then follow up Interpersonal therapy
A - ANHEDONIA Behavior
S - DISTRACTIBILITY
A - APPETITE CHANGE
D - DEPRESSED MOOD
F - FATIGUE
A - AGITATION
C - CONCENTRATION
E - ESTEEM LOW
S - SUICIDALITY

*2 week period

BIPOLAR 1 and 2 B1: Valproate 250 mg TID 7 days Cognitive Therapy

follow up
DIGFAST (3/7)
D DISTRACTIBILITY B2:
I INCREASED RISK TAKING BEHAVIOR Valproate 250 mg TID 7 days
G GRANDIOSITY follow up (hypomanic)
F FLIGHT OF IDEAS
A ACTIVITY INCREASED Fixed Fluoxetine 20 mg OD +
S SLEEP DECREASED Olanzapine 5 mg OD for 7 days
TALKATIVENESS follow up

Manic - at least one week

Hypomanic - at least 4 days, The episode is ​not ​severe enough to cause marked impairment in
social or occupational functioning or to necessitate hospitalization. If
there are psychotic features, the episode is, by definition, manic.
BRIEF PSYCHOTIC DISORDER Haloperidol Moderate disease:
A. Presence of one (or more) of the following symptoms. At least one of 0.5-2 mg q8-12hr initially; Severe
these must be (1), (2), or (3): disease: 3-5 mg q8-12hr initially ​1
1. Delusions month​ follow up
2. Hallucinations.
3. Disorganized speech (e.g., frequent derailment or Olanzapine 5 mg OD ​1 month
incoherence). follow up
4. Grossly disorganized or catatonic behavior.
**Note: Do not include a symptom if it is a culturally sanctioned response. Emergency: Haloperidol or
B. Duration of an episode of the disturbance is a​t least 1 day but less than 1month,​ with eventual Apriprazole IM
full return to premorbid level of functioning.
C. The disturbance is not better explained by major depressive or bipolar
disorder with psychotic features or another psychotic disorder such as schizophrenia or catatonia,
and is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a
medication) or another
medical condition.

SCHIZOPHRENIFORM DISORDER Risperidone 2-8 mg/daily once 7 Personal Therapy

A. Two (or more) of the following, each present for a significant portion of time during a 1- days follow up Supportive Therapy
month period (or less if successfully treated). At least one of these must be (1), (2), or (3):
1. Delusions. Emergency: Haloperidol or
2. Hallucinations. Apriprazole IM
3. Disorganized speech (e.g., frequent derailment or
incoherence).
4. Grossly disorganized or catatonic behavior.
5. Negative symptoms (i.e., diminished emotional expression or
avolition).
B. An episode of the disorder lasts ​at least 1 month but less than 6 months​. When the diagnosis
must be made without waiting for recovery, it should be qualified as “provisional.”
C. Schizoaffective disorder and depressive or bipolar disorder with psychotic features have been
ruled out because either 1) no major depressive or manic episodes have occurred concurrently
with the
active-phase symptoms, or 2) if mood episodes have occurred during active-phase symptoms, they
have been present for a minority of the total duration of the active and residual periods of the
illness.
D. The disturbance is not attributable to the physiological effects of a substance

SUBSTANCE INDUCED PSYCHOTIC DISORDER Haloperidol Moderate disease: Supportive Psychotherapy

A. Presence of one or both of the following symptoms: 0.5-2 mg q8-12hr initially; Severe Coping focused pyschotherapy
1. Delusions. disease: 3-5 mg q8-12hr initially ​1
2. Hallucinations​. month​ follow up
B. There is evidence from the history, physical examination, or laboratory findings of both (1)and
(2): Olanzepine 5-10 mg OD ​1 month
1. The symptoms in Criterion A developed during or soon after substance intoxication or follow up
withdrawal or after exposure to a medication. For agitation: 10 mg IM once
2. The involved substance/medication is capable of producing the symptoms in Criterion A.
C. The disturbance is not better explained by a psychotic disorder that is Emergency: Haloperidol or
not substance/medication-induced. Such evidence of an independent Apriprazole IM
psychotic disorder could include the following:
D. The symptoms preceded the onset of the substance/medication
use;
- The symptoms persist for a substantial period of time (e.g., about month) after the
cessation of acute withdrawal or severe intoxication; or, There is other evidence of an
independent nonsubstance/ medication induced psychotic disorder (e.g., a history of
recurrent non-substance/medication-related episodes).
D. The disturbance does not occur exclusively during the course of a delirium.
E. The disturbance causes clinically significant distress or impairment in social, occupational, or
other important areas of functioning
GENERALIZED ANXIETY DISORDER Fluoxetine 20 mg OD CBT
WATCHERS (4/6) Sertraline 50 mg OD ​7 days​ follow Support Pyschotherapy
W WORRY up
A AGITATION
T TENSION MUSCLES
C CONCENTRATION
H HYPER AROUSABILITY
E ENERGY DECREASED
R RESTLESSNESS
S SLEEP DISTURBANCE

*​In children only 1 item is required

*at least 6​ months

PTSD Fluoxetine 20 mg OD 7 days Trauma-focused Cognitive-

EIANA follow up *​suicide risk monitor Behavior Therapy- The treatment is
E EXPOSURE generally administered over 10-16
I INTRUSIVE SYMPTOMS (DREAMS) Citalopram 20-40 mg/day (chidlren treatment sessions
A AVOIDING REMINDERS (STIMULI) adolescents) 7 days follow up
N NEGATIVE ALTERATION (DISTORTED MEMORY, PERSISTENT NEGATIVE
STATE DETACHMENT) Paroxetine 20 mg OD ​1 month
A AROUSAL (HYPERVIGILANCE, STARTLE RESPONSE, SLEEP DISTURBANCE) follow up

*​1 month duration

PANIC DISORDER Alprazolam 05 mg q8 7 days Family Therapy
Peaks in ​minutes follow up Insigh Oriented Psychotherapy
(4/12)
1. Palpitations, pounding heart, or accelerated heart rate Paroxetine
2. Sweating o 10mg tab once a day (20mg if
3. Trembling or shaking social phobia)
4. Sensations of shortness of breath or smothering o For rapid effect: ALPRAZOLAM
5. Feelings of choking + SSRI
6. Chest pain or discomfort o For Panic Attack w/ depression:
7. Nausea or abdominal distress FLUOXETINE
8. Feeling dizzy, unsteady, light-headed, or faint o For Anticipation Anxiety:
9. Chills or heat sensations Clonazepam
10. Paresthesias (numbness or tingling sensations)
11. Derealization (feelings of unreality) or depersonalization (being
detached from oneself).
12. Fear of losing control or “going crazy.”
13. Fear of dying.

At least one of the attacks has been ​followed by 1 month​ (or more) of
one or both of the following:
1. Persistent concern or worry about additional panic attacks or
their consequences (e.g., losing control, having a heart attack,
“going crazy”)
2. A significant maladaptive change in behavior related to the
attacks (e.g., behaviors designed to avoid having panic attacks
 AGORAPHOBIA Alprazolam 05 mg q8 7 days Family Therapy
follow up Insighted Oriented Psychotherapy
A. Marked fear or anxiety about (​ 2/5​) of the following five
situations: Paroxetine
1. Using ​public transportatio​n (e.g., automobiles, buses, trains, o 10mg tab once a day (20mg if
ships, planes) social phobia)
2. Being in ​open spaces​ (e.g., parking lots, marketplaces, bridges) o For rapid effect: ALPRAZOLAM
3. Being in ​enclosed place​s (e.g., shops, theaters, cinemas) + SSRI
4. ​Standing in line or being in a crowd. o For Panic Attack w/ depression:
5. ​Being outside of the home alone. FLUOXETINE
o For Anticipation Anxiety:
*lasting 6​ months Clonazepam

OCD Fluvoxamine 50 mg OD 1 week Insight Oriented Therapy

A. Presence of compulsions and obsessions follow up Family Therapy
B. Obsessions and Compulsions are time consuming (take more than 1 hour per day) ECT

Notes:
Drugs that didn’t have specified durations to be taken, I just put 7 days then follow up para sure. Yung mga may 1 month, nasa handout na sila.